MX345150B - Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1. - Google Patents
Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1.Info
- Publication number
- MX345150B MX345150B MX2014011387A MX2014011387A MX345150B MX 345150 B MX345150 B MX 345150B MX 2014011387 A MX2014011387 A MX 2014011387A MX 2014011387 A MX2014011387 A MX 2014011387A MX 345150 B MX345150 B MX 345150B
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptides
- influenza
- optimized
- broadly reactive
- influenza viruses
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261617815P | 2012-03-30 | 2012-03-30 | |
| PCT/US2013/030530 WO2013148164A1 (en) | 2012-03-30 | 2013-03-12 | Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014011387A MX2014011387A (es) | 2014-10-14 |
| MX345150B true MX345150B (es) | 2017-01-18 |
Family
ID=49261015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014011387A MX345150B (es) | 2012-03-30 | 2013-03-12 | Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9212207B2 (enExample) |
| EP (1) | EP2831094B1 (enExample) |
| JP (1) | JP2015513902A (enExample) |
| KR (1) | KR20150004800A (enExample) |
| CN (1) | CN104395336B (enExample) |
| AU (1) | AU2013240365B2 (enExample) |
| BR (1) | BR112014023900A2 (enExample) |
| CA (1) | CA2868330A1 (enExample) |
| HK (1) | HK1203522A1 (enExample) |
| IN (1) | IN2014DN07399A (enExample) |
| MX (1) | MX345150B (enExample) |
| MY (1) | MY166953A (enExample) |
| RU (2) | RU2639551C2 (enExample) |
| SG (1) | SG11201406153XA (enExample) |
| WO (1) | WO2013148164A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2811103C (en) * | 2010-09-14 | 2020-01-14 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for influenza |
| JP6113155B2 (ja) | 2011-06-20 | 2017-04-12 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原 |
| JP2016505538A (ja) | 2012-11-27 | 2016-02-25 | ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | Ｈ１ｎ１インフルエンザに対する計算で最適化した広い反応性を示す抗原 |
| US20140286981A1 (en) * | 2013-03-14 | 2014-09-25 | Wisconsin Alumni Research Foundation | Broadly reactive mosaic peptide for influenza vaccine |
| WO2016100926A1 (en) * | 2014-12-19 | 2016-06-23 | Oregon Health & Science University | Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
| EP3233116A4 (en) * | 2014-12-19 | 2018-05-30 | Oregon Health & Science University | Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza |
| AU2016270979B2 (en) | 2015-06-02 | 2020-11-12 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
| WO2016201127A1 (en) | 2015-06-09 | 2016-12-15 | Sanofi Pasteur, Inc. | Methods of optimizing nucleotide sequences encoding engineered influenza proteins |
| WO2017053413A1 (en) * | 2015-09-21 | 2017-03-30 | Oregon Health & Science University | Vaccines intelligently produced by epitope recombination (viper) for influenza |
| EP3464328A1 (en) | 2016-06-02 | 2019-04-10 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
| EP3464327A1 (en) * | 2016-06-03 | 2019-04-10 | Sanofi Pasteur Inc. | Modification of engineered influenza hemagglutinin polypeptides |
| US11576964B2 (en) | 2018-03-28 | 2023-02-14 | Sanofi Pasteur Inc. | Methods of generating broadly protective vaccine compositions comprising hemagglutinin |
| US12521430B2 (en) | 2018-03-28 | 2026-01-13 | Sanofi Pasteur Inc. | Methods of generating broadly protective vaccine compositions comprising neuraminidase |
| WO2019195284A1 (en) | 2018-04-03 | 2019-10-10 | Sanofi | Antigenic influenza-ferritin polypeptides |
| JP2021519596A (ja) | 2018-04-03 | 2021-08-12 | サノフイＳａｎｏｆｉ | フェリチンタンパク質 |
| JP7337921B2 (ja) | 2018-11-06 | 2023-09-04 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | 鳥インフルエンザウイルスｈ５亜型に対する免疫原性組成物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0111830B8 (pt) | 2000-06-23 | 2021-05-25 | American Cyanamid Co | método de produção de partículas semelhantes ao vírus da influenza (vlps), vlps da influenza, vlps quiméricas, composições imunogênica e farmacêutica, e, usos de vlps da influenza e de vlps quiméricas |
| US20050181459A1 (en) | 2002-06-11 | 2005-08-18 | Matthew Baker | Method for mapping and eliminating T cell epitopes |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| CA2598884A1 (en) | 2005-02-24 | 2006-10-05 | University Of Massachusetts | Influenza nucleic acids, polypeptides, and uses thereof |
| BRPI0613625A2 (pt) | 2005-07-19 | 2011-01-18 | Dow Global Technologies Inc | vacinas da gripe recombinantes |
| US20090327170A1 (en) | 2005-12-19 | 2009-12-31 | Claudio Donati | Methods of Clustering Gene and Protein Sequences |
| US20080045472A1 (en) | 2006-03-31 | 2008-02-21 | Council Of Scientific And Industrial Research Bharat Biotech | Targets for human micro rnas in avian influenza virus (h5n1) genome |
| CA2663388C (en) | 2006-09-07 | 2017-01-17 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| TWI403518B (zh) * | 2007-01-23 | 2013-08-01 | Academia Sinica | 一種流感疫苗及其使用方法 |
| US8071561B2 (en) | 2007-08-16 | 2011-12-06 | Chrontech Pharma Ab | Immunogen platform |
| EP2217064A4 (en) | 2007-11-12 | 2012-10-03 | Univ Pennsylvania | NEW VACCINES FOR FIGHT AGAINST SEVERAL SUBTYPES OF INFLUENZA VIRUSES |
| EA034733B1 (ru) | 2008-01-21 | 2020-03-13 | Медикаго Инк. | Нуклеиновая кислота для увеличенной экспрессии гемагглютинина вируса гриппа в растении и ее применение |
| US7981428B2 (en) * | 2008-01-23 | 2011-07-19 | Academia Sinica | Flu vaccines and methods of use thereof |
| US20120034253A1 (en) | 2008-09-25 | 2012-02-09 | Fraunhofer Usa, Inc. | Influenza Vaccines, Antigens, Compositions, and Methods |
| WO2010036948A2 (en) * | 2008-09-26 | 2010-04-01 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Dna prime/inactivated vaccine boost immunization to influenza virus |
| KR101715418B1 (ko) | 2009-04-03 | 2017-03-10 | 메리얼 인코포레이티드 | 뉴캐슬 질환 바이러스-벡터를 이용한 조류 백신 |
| US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| CA2811103C (en) | 2010-09-14 | 2020-01-14 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for influenza |
| JP6113155B2 (ja) | 2011-06-20 | 2017-04-12 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原 |
| US9234008B2 (en) * | 2012-02-07 | 2016-01-12 | University of Pittsburgh—of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for H3N2, H2N2, and B influenza viruses |
| MY180109A (en) | 2012-02-13 | 2020-11-23 | Univ Pittsburgh Commonwealth Sys Higher Education | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
| JP2016505538A (ja) | 2012-11-27 | 2016-02-25 | ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | Ｈ１ｎ１インフルエンザに対する計算で最適化した広い反応性を示す抗原 |
-
2013
- 2013-03-12 EP EP13769077.2A patent/EP2831094B1/en not_active Not-in-force
- 2013-03-12 RU RU2014142785A patent/RU2639551C2/ru not_active IP Right Cessation
- 2013-03-12 HK HK15104016.5A patent/HK1203522A1/xx unknown
- 2013-03-12 JP JP2015503258A patent/JP2015513902A/ja active Pending
- 2013-03-12 WO PCT/US2013/030530 patent/WO2013148164A1/en not_active Ceased
- 2013-03-12 CA CA2868330A patent/CA2868330A1/en not_active Abandoned
- 2013-03-12 SG SG11201406153XA patent/SG11201406153XA/en unknown
- 2013-03-12 MY MYPI2014002785A patent/MY166953A/en unknown
- 2013-03-12 CN CN201380027311.0A patent/CN104395336B/zh not_active Expired - Fee Related
- 2013-03-12 US US14/388,726 patent/US9212207B2/en active Active
- 2013-03-12 MX MX2014011387A patent/MX345150B/es active IP Right Grant
- 2013-03-12 RU RU2017141447A patent/RU2017141447A/ru not_active Application Discontinuation
- 2013-03-12 AU AU2013240365A patent/AU2013240365B2/en not_active Ceased
- 2013-03-12 BR BR112014023900-2A patent/BR112014023900A2/pt not_active IP Right Cessation
- 2013-03-12 IN IN7399DEN2014 patent/IN2014DN07399A/en unknown
- 2013-03-12 KR KR1020147027594A patent/KR20150004800A/ko not_active Withdrawn
-
2015
- 2015-11-12 US US14/939,279 patent/US9555095B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2868330A1 (en) | 2013-10-03 |
| HK1203522A1 (en) | 2015-10-30 |
| AU2013240365B2 (en) | 2017-03-30 |
| RU2014142785A (ru) | 2016-05-20 |
| EP2831094A1 (en) | 2015-02-04 |
| IN2014DN07399A (enExample) | 2015-04-24 |
| US20160279226A1 (en) | 2016-09-29 |
| US20150017196A1 (en) | 2015-01-15 |
| EP2831094A4 (en) | 2015-10-14 |
| CN104395336B (zh) | 2018-01-23 |
| AU2013240365A1 (en) | 2014-10-23 |
| WO2013148164A1 (en) | 2013-10-03 |
| EP2831094B1 (en) | 2018-06-13 |
| US9555095B2 (en) | 2017-01-31 |
| KR20150004800A (ko) | 2015-01-13 |
| MX2014011387A (es) | 2014-10-14 |
| CN104395336A (zh) | 2015-03-04 |
| MY166953A (en) | 2018-07-25 |
| BR112014023900A2 (pt) | 2020-11-24 |
| SG11201406153XA (en) | 2014-10-30 |
| RU2639551C2 (ru) | 2017-12-21 |
| RU2017141447A (ru) | 2019-02-13 |
| JP2015513902A (ja) | 2015-05-18 |
| US9212207B2 (en) | 2015-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX345150B (es) | Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1. | |
| BR112014018884A2 (pt) | antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b | |
| BR112013032723A2 (pt) | antígenos amplamente reativos computacionalmente otimizados para influenza h1n1 | |
| MY180109A (en) | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza | |
| CY1122824T1 (el) | Πρωτεϊνες συντηξης και εμβολια συνδυασμου | |
| EA201201025A1 (ru) | Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них | |
| EA201591164A1 (ru) | Вакцины против вируса гриппа и их применение | |
| EA201391109A1 (ru) | Молекулы нуклеиновой кислоты, кодирующие новые антигены герпеса, вакцина, включающая их, и способы их использования | |
| MX339241B (es) | Vacunas novedosas contra sub-tipos multiples de virus de influenza. | |
| WO2013044203A3 (en) | Novel influenza hemagglutinin protein-based vaccines | |
| MX2013014109A (es) | Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria. | |
| CL2014003051A1 (es) | Anticuerpo de unión a hemaglutinina (ha) de diversos virus de la influenza; ácido nucleico que lo codifica; vector; célula huésped; método de elaboración; método de detección de virus de la influenza; composición farmacéutica; vacuna; y kit. | |
| EA201590860A1 (ru) | Варианты гемагглютинина и нейраминидазы вируса свиного гриппа | |
| EA201400235A1 (ru) | Вакцины против гриппа на основе н5 | |
| IN2015DN03070A (enExample) | ||
| WO2012082803A3 (en) | Method for inducing an immune response against avian, swine, spanish, h1n1, h5n9 influenza viruses and formulations thereof | |
| MX363149B (es) | Vacunas de nucleoproteina de la influenza. | |
| CO6541529A2 (es) | Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos | |
| BR112012029633A8 (pt) | Vetores do parapoxvírus contendo antígeno do vírus da raiva. | |
| MX2019007924A (es) | Vacunas contra la influenza. | |
| MX2015010763A (es) | Proteinas h5 del virus de la gripe h5n1 para uso como un medicamento. | |
| PL406631A1 (pl) | Antygen, szczepionka przeciwko grypie, układ do wytwarzania szczepionki, sposób wytwarzania antygenu oraz zastosowanie antygenu określonego powyżej do wytwarzania szczepionki przeciwko grypie | |
| EA201201620A1 (ru) | Способ получения рнк-вируса | |
| TH170760A (th) | แอนติเจนที่ทำปฏิกิริยาในวงกว้างที่มีการเพิ่มประสิทธิภาพโดยการคำนวณสำหรับ ไข้หวัดใหญ่ h1n1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |